HeartBeam, Inc. (NASDAQ: BEAT) President Eno Robert Paul recorded a purchase of 12,500 shares of the company's common stock on April 16, 2026, according to a Form 4 filed with the Securities and Exchange Commission. The shares were acquired at $0.80 apiece, bringing the cash value of the buy to $10,000.
The filing notes the purchase took place while the stock was trading near $0.81. That trading level followed a 29.6% decline in the share price over the prior week.
Following the acquisition, Mr. Paul directly holds 36,742 shares of HeartBeam. That total includes 23,333 vested Restricted Stock Units (RSUs), as detailed in the disclosure. The Form 4 specifies the buy was executed in connection with the company's underwritten public offering.
Recent capital markets activity
HeartBeam recently closed a public offering of 12.5 million shares that generated $10 million in gross proceeds, with the shares priced at $0.80 each. The offering was led by ClearCardio alongside participation from the company’s executive leadership, board members, and several institutional investors. Underwriters were granted a 30-day option to buy as many as 1.875 million additional shares to cover over-allotments.
The closing follows the company’s announcement of the offering and remains aligned with the customary closing conditions noted at the time of that announcement.
Analyst coverage and product notes
Two firms initiated coverage of HeartBeam in connection with recent market activity. B. Riley started coverage with a Buy rating and assigned a $4.00 price target, citing HeartBeam’s FDA-cleared device that can synthesize a clinical-grade 12-lead ECG from 3D signal capture. D. Boral Capital also began coverage with a Buy rating and set a $5.00 price target, highlighting the company’s development of ambulatory electrocardiogram technology.
According to InvestingPro analysis cited in disclosures, the stock appears undervalued at current levels; the platform is reported to offer 11 additional ProTips for BEAT, together with Fair Value analysis and Pro Research Reports covering this and other U.S. equities.
Contextual summary
The insider purchase by HeartBeam’s president, executed at $0.80 per share, took place concurrently with a recently completed offering priced at the same level and the launch of analyst coverage from two firms. The filing shows the purchase increased the president’s direct holdings and was tied to the company's financing activity.